{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:18:20Z","timestamp":1792783100144,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"The National Natural Science Foundation of China","award":["82003592"],"award-info":[{"award-number":["82003592"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"The National Natural Science Foundation of China","award":["92056201"],"award-info":[{"award-number":["92056201"]}],"id":[{"id":"https:\/\/ror.org\/01h0zpd94","id-type":"ROR","asserted-by":"crossref"}]},{"name":"R&D Program of Guangzhou National Laboratory","award":["GZNL2023A02012"],"award-info":[{"award-number":["GZNL2023A02012"]}],"id":[{"id":"https:\/\/ror.org\/03ybmxt82","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Key-Area Research and Development Program of Guangdong Province","award":["2022B1111050003"],"award-info":[{"award-number":["2022B1111050003"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-025-11240-4","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:12:13Z","timestamp":1749100333000},"page":"6895-6902","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Synthesis optimization of A2AAR antagonists: shortening the route to accelerate discovery"],"prefix":"10.1007","volume":"30","author":[{"given":"Wenjiang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianyong","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuhao","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taoda","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"issue":"21","key":"11240_CR1","doi-asserted-by":"publisher","first-page":"12196","DOI":"10.1021\/acs.jmedchem.0c00237","volume":"63","author":"F Yu","year":"2020","unstructured":"Yu F, Zhu C, Xie Q, Wang Y (2020) Adenosine A2A receptor antagonists for cancer immunotherapy: miniperspective. J Med Chem 63(21):12196\u201312212","journal-title":"J Med Chem"},{"key":"11240_CR2","doi-asserted-by":"publisher","first-page":"177535","DOI":"10.1016\/j.ejphar.2025.177535","volume":"997","author":"P Wang","year":"2025","unstructured":"Wang P, Ding W, Mo J, Gu C, Ouyang S, Peng K, Zhang Q, Liu G, Lu J, Wang Y, Hu W, Zhu K, Zhang X (2025) A novel adenosine 2A receptor antagonist HZ-086 enhances the efficiency of immunotherapy and alleviates the acquired resistance to PD-L1 by restoration of T cell functions. Eur J Pharmacol 997:177535","journal-title":"Eur J Pharmacol"},{"key":"11240_CR3","doi-asserted-by":"publisher","first-page":"107039","DOI":"10.1016\/j.ejps.2025.107039","volume":"207","author":"A Murugesan","year":"2025","unstructured":"Murugesan A, Smirnov A, Alonso AV, Buccioni M, Cui C, Dal Ben D, Francucci B, Lambertucci C, Marucci G, Volpini R, Konda Mani S, Devanesan S, AlSalhi MS, Yli-Harja O, Spinaci A, Kandhavelu M (2025) A2A receptor antagonist 4-(2-((6-amino-9-ethyl-8-(furan-2-Yl)-9H-purin-2-Yl)amino)ethyl)phenol, a promising adenosine derivative for glioblastoma treatment. Eur J Pharm Sci 207:107039","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"11240_CR4","first-page":"103446","volume":"9","author":"T Alonso-Gordoa","year":"2025","unstructured":"Alonso-Gordoa T, Goodman M, Vulsteke C, Roubaud G, Zhang J, Parikh M, Piulats JM, Azaro A, James GD, Cavazzina R, Gangl ET, Thompson J, Pouliot G, Kumar R, Sweeney C (2025) A phase II study (AARDVARC) of AZD4635 in combination with durvalumab and cabazitaxel in patients with progressive. Metastatic, Castration-Resistant Prostate Cancer ESMO Open 9(6):103446","journal-title":"Metastatic, Castration-Resistant Prostate Cancer ESMO Open"},{"issue":"4","key":"11240_CR5","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00262-024-03640-6","volume":"73","author":"GS Falchook","year":"2024","unstructured":"Falchook GS, Reeves J, Gandhi S, Spigel DR, Arrowsmith E, George DJ, Karlix J, Pouliot G, Hattersley MM, Gangl ET, James GD, Thompson J, Russell DL, Patel B, Kumar R, Lim E (2024) A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer. Cancer Immunol Immunother 73(4):7","journal-title":"Cancer Immunol Immunother"},{"issue":"22","key":"11240_CR6","doi-asserted-by":"publisher","first-page":"4871","DOI":"10.1158\/1078-0432.CCR-22-0612","volume":"28","author":"EA Lim","year":"2022","unstructured":"Lim EA, Bendell JC, Falchook GS, Bauer TM, Drake CG, Choe JH, George DJ, Karlix JL, Ulahannan S, Sachsenmeier KF, Russell DL, Moorthy G, Sidders BS, Pilling EA, Chen H, Hattersley MM, Das M, Kumar R, Pouliot GP, Patel MR (2022) Phase Ia\/b, open-label, multicenter study of AZD4635 (an adenosine A2A receptor antagonist) as monotherapy or combined with durvalumab, in patients with solid tumors. Clin Cancer Res 28(22):4871\u20134884","journal-title":"Clin Cancer Res"},{"issue":"12","key":"11240_CR7","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1038\/s41416-022-02013-z","volume":"127","author":"M Seifert","year":"2022","unstructured":"Seifert M, Benmebarek M-R, Briukhovetska D, M\u00e4rkl F, D\u00f6rr J, Cadilha BL, Jobst J, Stock S, Andreu-Sanz D, Lorenzini T, Gr\u00fcnmeier R, Oner A, Obeck H, Majed L, Dhoqina D, Feinendegen M, Gottschlich A, Zhang J, Schindler U, Endres S, Kobold S (2022) Impact of the selective A2AR and A2BR dual antagonist AB928\/etrumadenant on CAR T cell function. Br J Cancer 127(12):2175\u20132185","journal-title":"Br J Cancer"},{"issue":"5","key":"11240_CR8","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1007\/s11427-023-2459-8","volume":"67","author":"Y Weng","year":"2024","unstructured":"Weng Y, Yang X, Zhang Q, Chen Y, Xu Y, Zhu C, Xie Q, Wang Y, Yang H, Liu M, Lu W, Song G (2024) Structural insight into the dual-antagonistic mechanism of AB928 on adenosine A2 receptors. Sci China Life Sci 67(5):986\u2013995","journal-title":"Sci China Life Sci"},{"issue":"4","key":"11240_CR9","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s10637-018-0706-6","volume":"37","author":"L Seitz","year":"2019","unstructured":"Seitz L, Jin L, Leleti M, Ashok D, Jeffrey J, Rieger A, Tiessen RG, Arold G, Tan JBL, Powers JP, Walters MJ, Karakunnel J (2019) Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers. Invest New Drugs 37(4):711\u2013721","journal-title":"Invest New Drugs"},{"issue":"13","key":"11240_CR10","doi-asserted-by":"publisher","first-page":"8933","DOI":"10.1021\/acs.jmedchem.2c00101","volume":"65","author":"S Liu","year":"2022","unstructured":"Liu S, Ding W, Huang W, Zhang Z, Guo Y, Zhang Q, Wu L, Li Y, Qin R, Li J, Shi T, Zhang X, Lei J, Hu W (2022) Discovery of novel benzo[4,5]Imidazo[1,2- a ]pyrazin-1-amine-3-amide-one derivatives as anticancer human A2A adenosine receptor antagonists. J Med Chem 65(13):8933\u20138947","journal-title":"J Med Chem"},{"issue":"20","key":"11240_CR11","doi-asserted-by":"publisher","first-page":"12939","DOI":"10.1021\/acs.joc.8b02190","volume":"83","author":"R Ding","year":"2018","unstructured":"Ding R, Liu Y, Han M, Jiao W, Li J, Tian H, Sun B (2018) Synthesis of nitriles from primary amides or aldoximes under conditions of a catalytic swern oxidation. J Org Chem 83(20):12939\u201312944","journal-title":"J Org Chem"},{"issue":"46","key":"11240_CR12","doi-asserted-by":"publisher","first-page":"20529","DOI":"10.1002\/anie.202007209","volume":"59","author":"J Cai","year":"2020","unstructured":"Cai J, Hu J, Qin C, Li L, Shen D, Tian G, Zou X, Seeberger PH, Yin J (2020) Chemical synthesis elucidates the key antigenic epitope of the autism-related bacterium Clostridium Bolteae capsular octadecasaccharide. Angew Chem Int Ed 59(46):20529\u201320537","journal-title":"Angew Chem Int Ed"},{"issue":"1","key":"11240_CR13","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1038\/s41467-020-17350-x","volume":"11","author":"L-D Guo","year":"2020","unstructured":"Guo L-D, Zhang Y, Hu J, Ning C, Fu H, Chen Y, Xu J (2020) Asymmetric total synthesis of yuzurimine-type daphniphyllum alkaloid (+)-caldaphnidine. J Nat Commun 11(1):3538","journal-title":"J Nat Commun"},{"issue":"17","key":"11240_CR14","doi-asserted-by":"publisher","first-page":"6648","DOI":"10.1021\/acs.orglett.1c02188","volume":"23","author":"W-Y Tan","year":"2021","unstructured":"Tan W-Y, Lu Y, Zhao J-F, Chen W, Zhang H (2021) Oxidation of primary alcohols and aldehydes to carboxylic acids via hydrogen atom transfer. Org Lett 23(17):6648\u20136653","journal-title":"Org Lett"},{"key":"11240_CR15","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1039\/b713736m","volume":"9","author":"RA Sheldon","year":"2007","unstructured":"Sheldon RA (2007) The E factor: fifteen years on. Green Chem 9:1273\u20131283","journal-title":"Green Chem"},{"key":"11240_CR16","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1021\/acssuschemeng.7b03505","volume":"6","author":"RA Sheldon","year":"2018","unstructured":"Sheldon RA (2018) Metrics of green chemistry and sustainability: past, present, and future. ACS Sustain Chem Eng 6:32\u201348","journal-title":"ACS Sustain Chem Eng"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-025-11240-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-025-11240-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:01:57Z","timestamp":1791180117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-025-11240-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":16,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11240"],"URL":"https:\/\/doi.org\/10.1007\/s11030-025-11240-4","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"19 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Declarations"}}]}}